Lonafarnib Reduces the Resistance of Primitive Quiescent CML Cells to Imatinib Mesylate in Vitro

Leukemia - United Kingdom
doi 10.1038/sj.leu.2403785
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

CXCR4 Up-Regulation by Imatinib Induces Chronic Myelogenous Leukemia (CML) Cell Migration to Bone Marrow Stroma and Promotes Survival of Quiescent CML Cells

Molecular Cancer Therapeutics
Cancer ResearchOncology
2008English

Berbamine Exhibits Potent Antitumor Effects on Imatinib-Resistant CML Cells in Vitro and in Vivo

Acta Pharmacologica Sinica
MedicinePharmacology
2009English

Imatinib Mesylate Resistance Through BCR-ABL Independence in Chronic Myelogenous Leukemia

Cancer Research
Cancer ResearchOncology
2004English

Downregulation of Γ-Catenin Inhibits CML Cell Growth and Potentiates the Response of CML Cells to Imatinib Through Β-Catenin Inhibition

International Journal of Molecular Medicine
MedicineGenetics
2012English

CML: Langzeitresultate Zum Imatinib-Stopp

Im Focus Onkologie
2017English

MATE1 Regulates Cellular Uptake and Sensitivity to Imatinib in CML Patients

Blood Cancer Journal
OncologyHematology
2016English

Imatinib Mesylate Causes Growth Plate Closure in Vivo

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2009English

Contribution of BCR-ABL Kinase Domain Mutations to Imatinib Mesylate Resistance in Philadelphia Chromosome Positive Malaysian Chronic Myeloid Leukemia Patients

Hematology Reports
Hematology
2012English

A Novel BCR-Abl Splice Isoform Is Associated With the L248V Mutation in CML Patients With Acquired Resistance to Imatinib

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2006English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy